Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy.

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that teems with competition, both approved and ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Immunovant, Inc. (IMVT) announced on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...